en · de · es · pt
methods-notes.peptides4800.com › News › Thymosin Beta-4 Fragment Overview — Worked Examples

Thymosin Beta-4 Fragment Overview — Worked Examples

By Editorial Desk · published 2026-07-09 · last reviewed 2026-07-25 · News

If you have been reading about lyophilised powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.

Thymosin Beta-4 Fragment Overview

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized solid as supplied
Water solubilitySolubleDissolves in aqueous media
Typical storage temperature-20 °CDry powder, desiccated, protected from light
Typical analytical methodRP-HPLC with mass spectrometryPurity from peak area; mass for identity
Common synonymsTβ4 fragment; thymosin beta-4 fragmentNaming varies by supplier and catalogue

Handling, Storage and Analytical Checks

Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.

Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.

Related pages on this site

Handling, Storage, and Analysis

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.

Handling, Storage and Quality Checks

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Background from the literature

In DNA, fraying occurs when non-complementary regions exist at the end of an otherwise complementary double-strand of DNA. However, branched DNA can occur if a third strand of DNA is introduced and contains adjoining regions able to hybridize with the frayed regions of the pre-existing double-strand. Although the simplest example of branched DNA involves only three strands of DNA, complexes involving additional strands and multiple branches are also possible. Branched DNA can be used in nanotechnology to construct geometric shapes, see the section on uses in technology below.

=== Export markets === The front-wheel-drive 323 was introduced in Europe in September 1980, nearly simultaneously to its cousin and competitor the Ford Escort. The four-door saloon version followed in January 1981, and one month later automatic-equipped models became available to European buyers.

DNA-binding proteins are proteins that have DNA-binding domains and thus have a specific or general affinity for single- or double-stranded DNA. Sequence-specific DNA-binding proteins generally interact with the major groove of B-DNA, because it exposes more functional groups that identify a base pair.

Sources: en.wikipedia.org

Reference notes

On 28 May 2013, the Burnet Institute stated in the media that it recommends 24-hour access to sterile injecting equipment in the Melbourne suburb of Footscray after the area's drug culture continues to grow after more than ten years of intense law enforcement efforts. The institute's research concluded that public injecting behaviour is frequent in the area and inappropriately discarding injecting paraphernalia has been found in carparks, parks, footpaths and drives. Furthermore, people who inject drugs have broken open syringe disposal bins to reuse discarded injecting equipment. The British public body, the National Institute for Health and Care Excellence (NICE), introduced a new recommendation in early April 2014 due to an increase in the presentation of the number of young people who inject steroids at UK needle exchanges. NICE previously published needle exchange guidelines in 2009, in which needle and syringe services are not advised for people under the age of 18 years, but the organisation's director Professor Mike Kelly explained that a "completely different group" of people were presenting at programs. In the updated guidance, NICE recommended the provision of specialist services for "rapidly increasing numbers of steroid users", and that needles should be provided to people under the age of 18—a first for NICE—following reports of 15-year-old steroid injectors seeking to develop their muscles.

== Function and application == Due to the desirable properties of peptides such as high receptor affinity and bioactivity, and low toxicity, the use of peptides in therapeutics (i. e. as peptide therapeutics) has great potential; shown by a fast growing market with over 100 approved peptide-based drugs. The disadvantages are that peptides have low oral bioavailability and stability. Lipidation as a chemical modification tool in the development of therapeutic agents has proven to be useful in overcoming these issues, with four lipidized peptide drugs currently approved for use in humans, and various others in clinical trials. Two of the approved drugs are long-acting anti-diabetic GLP-1 analogues liraglutide (Victoza®), and insulin detemir (Levemir®). The other two are the antibiotics daptomycin and polymyxin B. Lipidated peptides also have applications in other areas, such as use in the cosmetic industry. A commercially available lipidated peptide, Matrixyl, is used in anti-wrinkle creams. Matrixyl is a pentapeptide and has the sequence KTTKS, with an attached palmitoyl lipid chain, that is able to stimulate collagen and fibronectin production in fibroblasts. Several studies have shown promising results of palmitoyl-KTTKS, and topical formulations have been found to significantly reduce fine lines and wrinkles, helping to delay the aging process in the skin.

== History == The Inner London Education Authority was established when the Greater London Council (GLC) replaced the London County Council (LCC) as the principal local authority for London in 1965. The LCC had, in 1904, taken over from the London School Board responsibility for education in Inner London. In what was to become Outer London, education was during the first half of the twentieth century primarily administered by the relevant county councils and county boroughs, with some functions delegated to second-tier councils in the area. The Herbert Commission report in 1960 recommended the establishment of the Greater London Council. It advocated a London-wide division of educational powers between the GLC and the London boroughs. The GLC would be responsible for strategic control of schools, and the boroughs for routine management. This part of the report was rejected by the government. Councils in the future Outer London area wanted greater control over education, preventing the creation of a London-wide local education authority (LEA), and there was strong opposition from teachers and other bodies to the idea of dividing up the LCC LEA. The London Government Act 1963 therefore created the ILEA to inherit the educational responsibilities of the LCC, and gave Outer London boroughs LEA status. The ILEA was originally conceived as a provisional body whose status would be reviewed before 1970, but the Labour government made its status permanent in 1965. The ILEA did not cover the small area of North Woolwich, where the LCC had provided a secondary school.

== Sources == Alhakim, Youssef (1983). Syria and the French Mandate (in Arabic). Beirut: Dar Al-Nahar. Bishour, Wadi' (1994). Syria: The Making of a State and the Birth of a Nation (in Arabic) (1st ed.). Damascus, Syria: Dar Al-Yaziji. Haddad, Ghassan Mohammed Rashad (2007). Shami Papers: Contemporary Syrian History 1946-1966 (in Arabic). Madbouly Library. ISBN 9789772086276. Archived from the original on 10 August 2020. Retrieved 9 February 2025. Torrey, Gordon (1964). Syrian Politics and the Military, 1945-1958. Ohio State University Press. Archived from the original on 10 August 2020.

Sources: en.wikipedia.org

Reference notes

=== Industrial scale === In a similar fashion to some laboratory methods, acetamide is produced by dehydrating ammonium acetate or via the hydration of acetonitrile, a byproduct of the production of acrylonitrile:

Staley was born as Layne Rutherford Staley on August 22, 1967, at Overlake Hospital in Bellevue, Washington, to Phillip Blair Staley and Nancy Elizabeth Staley (née Layne; later McCallum). Staley disliked his middle name "Rutherford" and would get angry every time someone called him by this name. He legally changed his middle name to "Thomas" during his teens because he was a fan of Mötley Crüe drummer Tommy Lee. Staley joined a rhythm band in Bellevue when he was two or three years old, and was the youngest in the group. At nine years old, he wrote in his Dr. Seuss book, All About Me, that he wanted to be a singer. Staley was seven years old when his parents divorced, after which he was raised by his mother and stepfather, Jim Elmer. He took his stepfather's surname while enrolled in Meadowdale High School in Lynnwood, and was known for some time as Layne Elmer. Staley was raised as a Christian Scientist. However, he was critical of religion in his adult life, stating in a 1991 interview:

Neighbouring countries were aware of the high levels of pollution in the Soviet Union but after the dissolution of the Soviet Union it was discovered that its environmental problems were greater than what the Soviet authorities admitted. The Soviet Union was the world's second-largest producer of harmful emissions. In 1988, total emissions in the Soviet Union were about 79% of those in the United States. But since the Soviet GNP was only 54% of that of the United States, this means that the Soviet Union generated 1.5 times more pollution than the United States per unit of GNP. The Chernobyl disaster in the Ukrainian SSR in 1986 was the first major accident at a civilian nuclear power plant. Unparalleled in the world, it resulted in a large number of radioactive isotopes being released into the atmosphere. Radioactive doses were scattered relatively far. Although long-term effects of the accident were unknown, 4,000 new cases of thyroid cancer which resulted from the accident's contamination were reported at the time of the accident, but this led to a relatively low number of deaths (WHO data, 2005). The disaster contributed to the socio-economic crises that resulted in the collapse of the Soviet Union. Another major radioactive accident that took place in the USSR was the Kyshtym disaster. The Kola Peninsula was one of the places with major problems. Around the industrial cities of Monchegorsk and Norilsk, where nickel, for example, is mined, all forests have been destroyed by contamination, while the northern and other parts of Russia have been affected by emissions.

Defects of spectrin, ankyrin (most commonly), or PROTEIN 4.2 lead to reduced structural integrity of the plasma membrane, destabilizing the overlying lipid bilayer, and releasing band 3-containing microvesicles. Band-3 is important for gas exchange (as seen above). Defects of band 3 lead to band 3 deficiency and loss of its lipid-stabilizing effect within the plasma membrane lipid bilayer. This results in the release of band 3-free microvesicles. Both pathways result in compromised plasma membrane integrity, decreased surface area, and formation of spherocytes with decreased mechanical compliance during circulation.

CH3COCl + 4 HF → CF3COF + 3 H2 + HCl CF3COF + H2O → CF3COOH + HF Wet samples can be dried by addition of trifluoroacetic anhydride. An older route to TFA proceeds via the oxidation of 1,1,1-trifluoro-2,3,3-trichloropropene with potassium permanganate. The trifluorotrichloropropene can be prepared by Swarts fluorination of hexachloropropene.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.

How does it differ from full thymosin beta-4?

The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.

Is human evidence available?

Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Network